Formulation Development
Atossa Therapeutics Announces Issuance of Key US Patent Covering Endoxifen
Atossa Therapeutics, Inc. recently announced the US Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy…
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. The positive final analysis included…
DNAnexus Secures $200-Million Funding to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine
DNAnexus, Inc. recently announced a $200-million financing round to accelerate the global adoption of its technology, translating the world’s complex multi-omics and clinical data into…
Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufacturing With HPAPI
Enteris BioPharma, Inc. recently announced the publication of a new white paper, titled HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity. The…
Alcami Adds Additional Formulation Development Capabilities
Alcami recently announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the…
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor in Human Skin Model of Vitiligo
VYNE Therapeutics Inc. recently announced positive preclinical data in an ex vivo skin model of vitiligo. In the preclinical model, pan-bromodomain and extra-terminal (BET) inhibitor…
Targovax ASA & Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON
Agenus and Targovax ASA recently announced they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines with Agenus´s clinically validated….
Harpoon Therapeutics Granted Orphan Drug Designation for Small Cell Lung Cancer Treatment
Harpoon Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, for the…
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial
Evaxion Biotech A/S has recently now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients…..
Cambrex Expands Biopharmaceutical Services Business
Cambrex recently announced it is significantly expanding its existing biopharmaceutical testing services business. The expansion includes 11 additional cGMP….
Evonik Increases Global Supply of Pharma-Grade Plant-Derived Cholesterol for mRNA Vaccines & Gene Therapies
Evonik has boosted its supply of plant-derived cholesterol, one of the most critical components for the manufacture of mRNA vaccines and gene therapies. The large-scale production of….
Exclusive License for Croda to Commercialize SSI’s CAF® Vaccine Adjuvants
Croda International Plc, which uses smart science to improve lives, recently announces it has entered a strategic collaboration with Statens Serum Institut (SSI), the leading…
Fulcrum Therapeutics Announces Phase 3 Clinical Trial
Fulcrum Therapeutics, Inc. recently announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD), in…
Aravive Announces Positive Updated Data & New Biomarker Data From Phase 1b Study
Aravive, Inc. recently announced positive new data from the Phase 1b portion of the ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell…
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Skye Bioscience, Inc. has recently entered into an agreement with Novotech Health Holdings for its upcoming Phase 1 study in Australia of its SBI-100 drug…
Pii Announces New President & Chief Executive Officer
Pharmaceutics International Inc (Pii) recently announced its Board of Directors has appointed Mr. John Fowler as President and Chief Executive Officer effective March 7, 2022.…
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma From Accure Therapeutics
Oculis S.A. and Accure Therapeutics recently announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to…
Harpoon Therapeutics Receives FDA Fast Track Designation
Harpoon Therapeutics, Inc. recently announced the US FDA has granted Fast Track designation to HPN217, a BCMA-targeting TriTAC, for the treatment of patients with relapsed,…
Aeterna Zentaris Announces Notice of Allowance for US Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism
Aeterna Zentaris Inc. recently announced that its licensor, The University of Sheffield, has received a notice of allowance from the USPTO for its patent application No. 16/608,611…..
Enteris BioPharma to Participate in DCAT® Week 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
